{"id":"https://openalex.org/W2053199643","doi":"https://doi.org/10.1046/j.1524-4733.2002.51052.x","title":"Cost-Effectiveness Analysis of Interferon Beta in Multiple Sclerosis: A Markov Process Analysis","display_name":"Cost-Effectiveness Analysis of Interferon Beta in Multiple Sclerosis: A Markov Process Analysis","publication_year":2002,"publication_date":"2002-01-01","ids":{"openalex":"https://openalex.org/W2053199643","doi":"https://doi.org/10.1046/j.1524-4733.2002.51052.x","mag":"2053199643","pmid":"https://pubmed.ncbi.nlm.nih.gov/11873383"},"language":"en","primary_location":{"id":"doi:10.1046/j.1524-4733.2002.51052.x","doi":"https://doi.org/10.1046/j.1524-4733.2002.51052.x","is_oa":true,"landing_page_url":"https://doi.org/10.1046/j.1524-4733.2002.51052.x","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://doi.org/10.1046/j.1524-4733.2002.51052.x","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062818266","display_name":"Mark J. C. Nuijten","orcid":"https://orcid.org/0000-0003-2888-1033","observed_orcids":["https://orcid.org/0000-0003-2888-1033"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark J.C. Nuijten","raw_affiliation_strings":["MEDTAP International, Dorpsstraat 75, 1546 LG Jisp, Amsterdam, Netherlands. nuijten@medtap.nl","MEDTAP International, Amsterdam, the Netherlands;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MEDTAP International, Dorpsstraat 75, 1546 LG Jisp, Amsterdam, Netherlands. nuijten@medtap.nl","institution_ids":[]},{"raw_affiliation_string":"MEDTAP International, Amsterdam, the Netherlands;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110358211","display_name":"John Hutton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Hutton","raw_affiliation_strings":["MEDTAP International, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MEDTAP International, London, United Kingdom","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":null,"fwci":16.1585,"has_fulltext":false,"cited_by_count":64,"citation_normalized_percentile":{"value":0.98751723,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"5","issue":"1","first_page":"44","last_page":"54"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.8970000147819519,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.8970000147819519,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.10159999877214432,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T14138","display_name":"Life Cycle Costing Analysis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1402","display_name":"Accounting"},"field":{"id":"https://openalex.org/fields/14","display_name":"Business, Management and Accounting"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interferon-beta","display_name":"interferon-beta","score":0.9539999961853027},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.9980000257492065},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9139999747276306},{"id":"https://openalex.org/keywords/prophylaxis","display_name":"prophylaxis","score":0.7979999780654907},{"id":"https://openalex.org/keywords/relapsing-remitting-multiple-sclerosis","display_name":"relapsing-remitting multiple sclerosis","score":0.9639999866485596},{"id":"https://openalex.org/keywords/secondary-progressive-multiple-sclerosis","display_name":"secondary progressive multiple sclerosis","score":1.0},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.9850000143051147},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8399999737739563},{"id":"https://openalex.org/keywords/national-health-service","display_name":"National Health Service","score":0.6320000290870667},{"id":"https://openalex.org/keywords/health-economics","display_name":"health economics","score":0.43299999833106995}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.836733341217041},{"id":"https://openalex.org/C2994247566","wikidata":"https://www.wikidata.org/wiki/Q2450337","display_name":"Interferon beta","level":3,"score":0.7879927158355713},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.6673420667648315},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.5414876937866211},{"id":"https://openalex.org/C2910198813","wikidata":"https://www.wikidata.org/wiki/Q1851162","display_name":"Interferon beta-1b","level":4,"score":0.51697838306427},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.4975922405719757},{"id":"https://openalex.org/C515549039","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost-effectiveness analysis","level":3,"score":0.48793289065361023},{"id":"https://openalex.org/C184834754","wikidata":"https://www.wikidata.org/wiki/Q358564","display_name":"Cost\u2013utility analysis","level":3,"score":0.46250078082084656},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.45163920521736145},{"id":"https://openalex.org/C2908698914","wikidata":"https://www.wikidata.org/wiki/Q2450337","display_name":"Interferon beta-1a","level":4,"score":0.4515116810798645},{"id":"https://openalex.org/C2776125615","wikidata":"https://www.wikidata.org/wiki/Q18391886","display_name":"Economic evaluation","level":2,"score":0.4191814064979553},{"id":"https://openalex.org/C163836022","wikidata":"https://www.wikidata.org/wiki/Q6771326","display_name":"Markov model","level":3,"score":0.4172499179840088},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3527294099330902},{"id":"https://openalex.org/C98763669","wikidata":"https://www.wikidata.org/wiki/Q176645","display_name":"Markov chain","level":2,"score":0.26911211013793945},{"id":"https://openalex.org/C105795698","wikidata":"https://www.wikidata.org/wiki/Q12483","display_name":"Statistics","level":1,"score":0.15799081325531006},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.15681475400924683},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.08993345499038696},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.07000812888145447},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000276","descriptor_name":"Adjuvants, Immunologic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000276","descriptor_name":"Adjuvants, Immunologic","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000276","descriptor_name":"Adjuvants, Immunologic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000367","descriptor_name":"Age Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003365","descriptor_name":"Costs and Cost Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008390","descriptor_name":"Markov Chains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D012737","descriptor_name":"Sex Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015337","descriptor_name":"Multicenter Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016899","descriptor_name":"Interferon-beta","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016899","descriptor_name":"Interferon-beta","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D016899","descriptor_name":"Interferon-beta","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1046/j.1524-4733.2002.51052.x","doi":"https://doi.org/10.1046/j.1524-4733.2002.51052.x","is_oa":true,"landing_page_url":"https://doi.org/10.1046/j.1524-4733.2002.51052.x","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},{"id":"pmid:11873383","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11873383","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","raw_type":"Comparative Study"}],"best_oa_location":{"id":"doi:10.1046/j.1524-4733.2002.51052.x","doi":"https://doi.org/10.1046/j.1524-4733.2002.51052.x","is_oa":true,"landing_page_url":"https://doi.org/10.1046/j.1524-4733.2002.51052.x","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":41,"referenced_works":["https://openalex.org/W62276965","https://openalex.org/W135353536","https://openalex.org/W1552329178","https://openalex.org/W1554701668","https://openalex.org/W1964903075","https://openalex.org/W1967276269","https://openalex.org/W1975104912","https://openalex.org/W1994115946","https://openalex.org/W1996979333","https://openalex.org/W2007948644","https://openalex.org/W2022826476","https://openalex.org/W2032404313","https://openalex.org/W2036853725","https://openalex.org/W2040960686","https://openalex.org/W2042615005","https://openalex.org/W2061097019","https://openalex.org/W2061317386","https://openalex.org/W2077726369","https://openalex.org/W2078096723","https://openalex.org/W2078358029","https://openalex.org/W2083507939","https://openalex.org/W2085004729","https://openalex.org/W2086821310","https://openalex.org/W2095081886","https://openalex.org/W2097669496","https://openalex.org/W2111139513","https://openalex.org/W2116810340","https://openalex.org/W2119500075","https://openalex.org/W2139367012","https://openalex.org/W2145185401","https://openalex.org/W2169098250","https://openalex.org/W2340533542","https://openalex.org/W2404245847","https://openalex.org/W2416029517","https://openalex.org/W2704729794","https://openalex.org/W2752395422","https://openalex.org/W3036563658","https://openalex.org/W4210548604","https://openalex.org/W4250145052","https://openalex.org/W4299159248","https://openalex.org/W6680286436"],"related_works":["https://openalex.org/W2041303580","https://openalex.org/W2090997299","https://openalex.org/W2073321077","https://openalex.org/W2016252920","https://openalex.org/W4299159248","https://openalex.org/W2134342836","https://openalex.org/W2345531132","https://openalex.org/W2117722893","https://openalex.org/W7095966180","https://openalex.org/W7097687868"],"abstract_inverted_index":null,"counts_by_year":[{"year":2024,"cited_by_count":4},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}